Chimeric antigen receptor therapy meets mRNA technology.

Chimeric antigen receptor therapy meets mRNA technology.

Publication date: Sep 21, 2023

Genetically engineered immune cells expressing chimeric antigen receptors (CARs) have emerged as a new game changer in cancer immunotherapy. The utility of CAR T cell therapy against hematological malignancies has been validated in clinical practice. Other CAR immune cells are currently under investigation to improve the potency of CAR therapy in solid tumors. As a new class of therapeutic modalities, mRNA-based therapeutics hold enormous potential beyond COVID-19 mRNA vaccines. Arming immune cells with mRNA-encoded CARs represents a new frontier in cancer and beyond, enabling in vivo generation of CAR cells without causing transgene integration. In this review, we summarize recent advances in mRNA-based CAR immunotherapies and highlight their opportunities and challenges for the development of a new generation of living drugs.

Concepts Keywords
Biotechnol chimeric antigen receptor
Cars delivery system
Hematological immune cell
Mrna immunotherapy
Vaccines mRNA


Type Source Name
disease MESH cancer
disease IDO cell
disease MESH hematological malignancies
disease MESH COVID-19

Original Article

(Visited 2 times, 1 visits today)